Top Innovation Stock
Today's stock market report features an AI Robotics tech stock with a $4 million order backlog.
Click here for the name and ticker
Roxanne Lagano net worth and biography

Roxanne Lagano Biography and Net Worth

EVP of Zoetis

Roxanne Lagano was appointed executive vice president and chief human resources officer at Zoetis in November 2012. In this role, she is responsible for the company's worldwide human resources management and policies, colleague experience and award-winning workplace.

Ms. Lagano was given responsibility for the Global Operations and Security functions in 2020, and previously had oversight for the company’s Corporate Communications function from 2015-2019.

Prior to joining Zoetis, Ms. Lagano was senior vice president, Global Compensation, Benefits and Wellness for Pfizer. In that role, Ms. Lagano was responsible for the design and implementation of Pfizer's compensation and employee benefit programs around the globe. She was also responsible for Pfizer's wellness strategies, including the Healthy Pfizer program, and for the human resources aspects of the company's merger, acquisition and divestiture activities.

Ms. Lagano joined Pfizer in 1997 as manager, Tax Planning, after specializing in employee benefits, executive compensation and mergers and acquisitions at Schulte, Roth and Zabel, LLP, a New York law firm.

After joining Pfizer's legal division in 1999, Ms. Lagano joined Pfizer's Human Resources organization in 2000. During her time in HR for Pfizer, Ms. Lagano held various positions of increasing responsibility, including senior director of business transactions (HR) and senior director, employee benefits.

Ms. Lagano holds a bachelor’s degree from Long Island University and a Juris Doctor degree from Hofstra University School of Law.

What is Roxanne Lagano's net worth?

The estimated net worth of Roxanne Lagano is at least $3.68 million as of July 22nd, 2022. Ms. Lagano owns 23,687 shares of Zoetis stock worth more than $3,681,907 as of December 5th. This net worth approximation does not reflect any other assets that Ms. Lagano may own. Learn More about Roxanne Lagano's net worth.

How old is Roxanne Lagano?

Ms. Lagano is currently 57 years old. There are 7 older executives and no younger executives at Zoetis. Learn More on Roxanne Lagano's age.

How do I contact Roxanne Lagano?

The corporate mailing address for Ms. Lagano and other Zoetis executives is 10 Sylvan Way, Parsippany NJ, 07054. Zoetis can also be reached via phone at (973) 822-7000 and via email at [email protected] Learn More on Roxanne Lagano's contact information.

Has Roxanne Lagano been buying or selling shares of Zoetis?

Roxanne Lagano has not been actively trading shares of Zoetis in the last ninety days. Most recently, Roxanne Lagano sold 2,167 shares of the business's stock in a transaction on Friday, July 22nd. The shares were sold at an average price of $180.26, for a transaction totalling $390,623.42. Following the completion of the sale, the executive vice president now directly owns 23,687 shares of the company's stock, valued at $4,269,818.62. Learn More on Roxanne Lagano's trading history.

Who are Zoetis' active insiders?

Zoetis' insider roster includes Juan Alaix (Director), Heidi Chen (EVP), Glenn David (EVP), Andrew Fenton (EVP), Wetteny Joseph (Exec. VP & CFO ), Robert Kelly (EVP), Catherine Knupp (EVP), Roxanne Lagano (EVP), Clinton Lewis, Jr. (EVP), Gregory Norden (Director), Kristin Peck (CEO), Willie Reed (Director), Linda Rhodes (Director), Robert Scully (Director), and Roman Trawicki (EVP). Learn More on Zoetis' active insiders.

Are insiders buying or selling shares of Zoetis?

In the last twelve months, insiders at the sold shares 11 times. They sold a total of 72,293 shares worth more than $13,563,344.69. The most recent insider tranaction occured on July, 22nd when EVP Roxanne Lagano sold 2,167 shares worth more than $390,623.42. Insiders at Zoetis own 0.1 % of the company. Learn More about insider trades at Zoetis.

Information on this page was last updated on 7/22/2022.

Roxanne Lagano Insider Trading History at Zoetis

Transaction DateBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
7/22/2022Sell2,167$180.26$390,623.4223,687View SEC Filing Icon  
6/27/2022Sell4,334$175.00$758,450.0023,687View SEC Filing Icon  
4/26/2022Sell2,167$178.96$387,806.3223,687View SEC Filing Icon  
2/15/2022Sell2,065$196.54$405,855.10View SEC Filing Icon  
12/23/2021Sell1,315$241.70$317,835.50View SEC Filing Icon  
11/23/2021Sell1,315$223.09$293,363.35View SEC Filing Icon  
10/22/2021Sell1,315$208.03$273,559.45View SEC Filing Icon  
9/23/2021Sell1,315$202.17$265,853.55View SEC Filing Icon  
8/23/2021Sell9,603$207.07$1,988,493.21View SEC Filing Icon  
7/22/2021Sell22,450$199.18$4,471,591.00View SEC Filing Icon  
5/19/2021Sell6,000$169.05$1,014,300.0053,642View SEC Filing Icon  
11/19/2020Sell6,000$164.06$984,360.0041,680View SEC Filing Icon  
8/19/2020Sell6,000$160.37$962,220.0041,680View SEC Filing Icon  
5/19/2020Sell4,463$131.02$584,742.2640,143View SEC Filing Icon  
11/19/2019Sell4,463$118.99$531,052.3733,190View SEC Filing Icon  
8/19/2019Sell4,463$125.99$562,293.3733,190View SEC Filing Icon  
5/10/2019Sell29,453$101.65$2,993,897.4558,180View SEC Filing Icon  
4/1/2019Sell2,000$101.89$203,780.0030,727View SEC Filing Icon  
12/31/2018Sell2,000$85.30$170,600.00View SEC Filing Icon  
12/31/2018Sell2,000$85.30$170,600.0022,023View SEC Filing Icon  
10/1/2018Sell2,000$92.03$184,060.00View SEC Filing Icon  
7/2/2018Sell2,000$84.76$169,520.0022,023View SEC Filing Icon  
2/21/2018Sell35,663$81.02$2,889,416.2649,919View SEC Filing Icon  
11/8/2016Sell9,797$50.43$494,062.718,063View SEC Filing Icon  
See Full Table

Roxanne Lagano Buying and Selling Activity at Zoetis

This chart shows Roxanne Lagano's buying and selling at Zoetis by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

Zoetis Company Overview

Zoetis logo
Zoetis Inc. discovers, develops, manufactures, and commercializes animal health medicines, vaccines, and diagnostic products in the United States and internationally. It commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep; and companion animals comprising dogs, cats, and horses. The company also offers vaccines, which are biological preparations to prevent diseases of the respiratory, gastrointestinal, and reproductive tracts or induce a specific immune response; anti-infectives that prevent, kill, or slow the growth of bacteria, fungi, or protozoa; and parasiticides that prevent or eliminate external and internal parasites, which include fleas, ticks, and worms. It also provides other pharmaceutical products that comprise pain and sedation, antiemetic, reproductive, and oncology products; dermatology products for itch associated with allergic conditions and atopic dermatitis; and medicated feed additives, which offer medicines to livestock. In addition, the company provides portable blood and urine analysis testing, including point-of-care diagnostic products, instruments and reagents, rapid immunoassay tests, reference laboratory kits and services, and blood glucose monitors; and other non-pharmaceutical products, including nutritionals and agribusiness services, as well as products and services in areas, such as biodevices, genetics tests, and precision animal health. It markets its products to veterinarians, livestock producers, and retail outlets, as well as third-party veterinary distributors through its sales representatives, and technical and veterinary operations specialists. The company was founded in 1952 and is headquartered in Parsippany, New Jersey.
Read More

Today's Range

Now: $155.44
Low: $154.63
High: $156.47

50 Day Range

MA: $147.98
Low: $131.14
High: $157.42

2 Week Range

Now: $155.44
Low: $124.15
High: $249.27

Volume

73,321 shs

Average Volume

2,185,833 shs

Market Capitalization

$72.45 billion

P/E Ratio

35.49

Dividend Yield

0.83%

Beta

0.72